Search research articles
Contact Us
Filters
Showing results (1-10 of 75) with videos related to
Page
of 8
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
Targeting CD20: teaching an old dog new tricks
Jeff P Sharman
Blood Reviews
|
April 30, 2022
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
Juan Pablo Alderuccio, Jeff P Sharman
JCO Oncology Practice
|
June 7, 2024
Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia
Bruce D Cheson, Jeff P Sharman
Current Oncology Reports
|
April 13, 2018
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents
Joanna Rhodes, Anthony Mato, Jeff P Sharman
Future Oncology (London, England)
|
January 24, 2022
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study
Jeff P Sharman, Carol F Kirchhoff, Robert M Rifkin
Journal of General Internal Medicine
|
May 4, 2007
Effectiveness of warfarin among patients with cancer
Adam J Rose, Jeff P Sharman, Al Ozonoff, et al.
Leukemia & Lymphoma
|
May 24, 2023
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
Jeff P Sharman, Paulo Miranda, Jack Roos, et al.
British Journal of Haematology
|
April 18, 2024
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib
Jeff P Sharman, Paolo Ghia, Paulo Miranda, et al.
Future Oncology (London, England)
|
July 20, 2022
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Andrew Davies, Arnon P Kater, Jeff P Sharman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
December 11, 2019
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera<sup>®</sup>) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Jeff P Sharman, Anna Marina Liberati, Kenichi Ishizawa, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 75) with videos related to
Sort By:
Page
of 8
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
Targeting CD20: teaching an old dog new tricks
Jeff P Sharman
Blood Reviews
|
April 30, 2022
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
Juan Pablo Alderuccio, Jeff P Sharman
JCO Oncology Practice
|
June 7, 2024
Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia
Bruce D Cheson, Jeff P Sharman
Current Oncology Reports
|
April 13, 2018
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents
Joanna Rhodes, Anthony Mato, Jeff P Sharman
Future Oncology (London, England)
|
January 24, 2022
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study
Jeff P Sharman, Carol F Kirchhoff, Robert M Rifkin
Journal of General Internal Medicine
|
May 4, 2007
Effectiveness of warfarin among patients with cancer
Adam J Rose, Jeff P Sharman, Al Ozonoff, et al.
Leukemia & Lymphoma
|
May 24, 2023
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
Jeff P Sharman, Paulo Miranda, Jack Roos, et al.
British Journal of Haematology
|
April 18, 2024
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib
Jeff P Sharman, Paolo Ghia, Paulo Miranda, et al.
Future Oncology (London, England)
|
July 20, 2022
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Andrew Davies, Arnon P Kater, Jeff P Sharman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
December 11, 2019
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera<sup>®</sup>) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Jeff P Sharman, Anna Marina Liberati, Kenichi Ishizawa, et al.
Page
of 8